What exactly is 'chronic Lyme disease' — and why is it so controversial?
Chronic Lyme disease (CLD) is a term used to describe patients who have long-term symptoms such as fatigue, joint pain, muscle aches, memory problems, and sleep disturbances, which they attribute to a past or ongoing Lyme infection. However, there is no universally accepted definition. One review notes that CLD is 'one of the most controversial-contested illnesses' and that mainstream medical authorities have 'unalterably negated' it as a disease entity [3]. The core controversy is whether these symptoms are caused by a persistent bacterial infection (Borrelia burgdorferi) or by other mechanisms like autoimmune reactions or misdiagnosis of other conditions.
A 2025 clinical case report describes a patient with long-term joint and neurological symptoms who tested positive for Borrelia antibodies years after a tick bite, even though they had no classic Lyme symptoms like a rash or arthritis at the time [6]. This illustrates that some patients do have evidence of past infection, but the symptoms may be due to an ongoing immune response rather than active bacteria. The same report states that 'most researchers explain the occurrence of CLD by the induction of autoimmune reactions' [6].
What does the research actually show about CLD patients and their symptoms?
The evidence consistently shows that CLD patients are a distinct group from those with confirmed Lyme disease. A 2009 study found that patients diagnosed with CLD were significantly more likely to be female than patients with either confirmed Lyme disease (odds ratio 2.42) or post-Lyme disease syndrome (odds ratio 2.32) [5]. This suggests that conditions with a female preponderance, such as fibromyalgia, chronic fatigue syndrome, or depression, may be misdiagnosed as CLD [5].
A 2022 focus group study with 15 self-identified CLD patients found that they experience significant, 'invisible' symptoms that severely impact work, social life, and relationships [4]. Nearly all participants reported negative experiences with healthcare providers, feeling misunderstood or abandoned [4]. This highlights that while the condition is medically contested, the suffering is real.
A 2024 study used machine learning to differentiate long COVID from CLD based on immune markers (cytokines), achieving 97% sensitivity and 90% specificity [2]. This shows that CLD has a distinct biological signature compared to other post-infectious syndromes, lending some support to its existence as a separate condition.
Are there any proven treatments for chronic Lyme disease?
There is no FDA-approved or widely accepted treatment for CLD. A 2025 review of disulfiram (a drug used for alcohol use disorder) as a potential treatment concluded that 'clinical evidence is insufficient' and that 'disulfiram therapy for the treatment option of CLD is not advised' due to severe adverse reactions [3]. This is despite patients and some 'Lyme-literate' physicians seeking it out [3].
A 2025 pilot study tested the anti-inflammatory supplement Pycnogenol in 40 CLD patients. After 6 months, the Pycnogenol group had significantly fewer symptoms (e.g., joint pain, fatigue) and lower inflammation markers (ESR) compared to the control group [1]. For example, only 10% of the Pycnogenol group needed corticosteroids versus 45% of controls [1]. However, this was a small, non-randomized registry study, not a definitive trial.
The clinical case report [6] described successful treatment of a CLD patient with the antidepressant duloxetine (30 mg/day) and non-steroidal anti-inflammatory drugs only as needed, leading to symptom minimization over a year. This suggests that symptom management, rather than anti-infective therapy, may be the most effective approach for many patients.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2009 to 2025, 4 from 2024 or later, 3 in Q1 journals — selected as the most relevant from 6 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Supplementary management of chronic Lyme disease with Pycnogenol®
In a 40-patient pilot registry study, Pycnogenol (150 mg/day for 6 months) significantly reduced symptoms, inflammation (ESR), and oxidative stress in CLD patients compared to standard management alone, with fewer patients needing corticosteroids (10% vs 45%).
Long COVID diagnostic with differentiation from chronic lyme disease using machine learning and cytokine hubs
A machine-learning model using cytokine hubs differentiated long COVID from chronic Lyme disease with 97% sensitivity and 90% specificity in a validation set of 124 individuals, suggesting CLD has a distinct immune profile.
REPURPOSING DISULFIRAM AS A TREATMENT OPTION OF "CHRONIC LYME DISEASE": A REVIEW
A narrative review concluded that chronic Lyme disease is a poorly defined, controversial condition with many differential diagnoses, and that disulfiram therapy is not advised due to insufficient evidence and severe adverse reactions.
Knowing the entire story – a focus group study on patient experiences with chronic Lyme-associated symptoms (chronic Lyme disease)
A focus group study with 15 CLD patients found they experience significant, invisible symptoms, severe life impact, and near-universal negative experiences with healthcare providers, feeling abandoned and not heard.
Implications of gender in chronic Lyme disease.
A cross-sectional study of 490 CLD patients found they were significantly more likely to be female than patients with confirmed Lyme disease (odds ratio 2.42) or post-Lyme disease syndrome (odds ratio 2.32), suggesting misdiagnosis of conditions like fibromyalgia or chronic fatigue.
Chronic Lyme Disease. Clinical case
A 2025 clinical case report describes a CLD patient with positive Borrelia antibodies and long-term joint/neurological symptoms who improved with duloxetine and as-needed NSAIDs, noting that most researchers attribute CLD to autoimmune reactions rather than persistent infection.